演題抄録

ポスター

開催概要
開催回
第56回・2018年・横浜
 

化学療法未施行の去勢抵抗性前立腺癌に対するエンザルタミドの臨床的検討

演題番号 : P43-3

[筆頭演者]
演者)白石 匠:1 
[共同演者]
高村 俊哉:1、上野 彰久:1、山田 剛司:1、鈴木 啓:1、藤原 敦子:1、金沢 元洪:1、牛嶋 壮:1、内藤 泰行:1、本郷 文弥:1、沖原 宏冶:2、浮村 理:1

1:京都府立医科大学・泌尿器科、2:京都府立医科大学・北部医療センター・泌尿器科

 

Background: Enzalutamide is an oral androgen-receptor inhibitor that prolongs survival in men with castration-resistant prostate cancer (CRPC) in whom the disease has progressed after androgen-deprivation therapy. We investigated oncological outcomes and clinicopathological factors related to overall survival in chemotherapy-naïve patients with CRPC who received enzalutamide treatment.
Methods: Seventy-seven CRPC patients who received enzalutamide treatment before chemotherapy were retrospectively assessed. Factors associated with overall survival after enzalutamide administration were analyzed.
Results: The median age at the time of treatment was 76 years old (range, 55 to 95). Initial PSA before enzalutamide treatment was a median of 7.16 ng/ml (range, 0.17 to 2081.86). Bone, lymph node, and visceral metastasis were observed in 64.3%, 31.4% and 2.9%, respectively. Four weeks after initiation of the treatment, 30%, 50% and 70% of PSA decrease were observed in 56.9%, 47.2% and 30.6% of patients, respectively. After enzalutamide treatment, abiraterone, docetaxel and cabazitaxel were administered in 40.3%, 35.1% and 14.3%, respectively. Overall survival was significantly associated with existence of bone metastasis and base-line PSA at the time of enzalutamide treatment and any PSA decrease less than base-line at the 4 weeks after initiation of the treatment. Any PSA decrease at the time of 4 weeks after initiation of the treatment was an independent prognostic factor that was associated with overall survival. Nineteen patients died of the disease with a median follow-up period of 16 months (range, 1 to 44).
Conclusion: PSA decrease less than base-line at the 4 weeks after introduction of enzalutamide in chemotherapy-naïve patients with CRPC could be important to have a better outcome.

キーワード

臓器別:前立腺・男性生殖器

手法別:内分泌・ホルモン療法

前へ戻る